Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Adalimumab

adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26

DRUG

Methotrexate

methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26

Trial Locations (11)

22027

Rhumatologie, CH de SAINT BRIEUC, Saint-Brieuc

29609

Rhumatologie, CHRU de BREST, Brest

35203

Rhumatologie, CHRU de RENNES, Rennes

37044

Rhumatologie, CHRU de TOURS, Tours

41000

Rhumatologie, CH de BLOIS, Blois

44093

Rhumatologie, CHRU de NANTES, Nantes

44606

Médecine polyvalente, CH de SAINT NAZAIRE, Saint-Nazaire

45032

Rhumatologie / IPROS, CHR d'ORLEANS, Orléans

72037

Rhumatologie, CHR du MANS, Le Mans

85925

Rhumatologie, CHD LA ROCHE SUR YON, La Roche-sur-Yon

86021

Rhumatologie, CHRU de POITIERS, Poitiers

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT01895764 - Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) | Biotech Hunter | Biotech Hunter